Press Releases
Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57%...
INDIANAPOLIS, May 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to...
Press Releases
Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies
INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research...
Press Releases
Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Deutsche Bank Global Health Care Conference on Wednesday, May 6, 2015, in Boston. Giovanni...
Press Releases
Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts
INDIANAPOLIS, May 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced plans to establish a new drug delivery and device innovation center in...
Press Releases
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in...
Press Releases
Lilly Declares Second-Quarter 2015 Dividend
INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter...
Press Releases
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma
Application includes CheckMate -066, a clinical trial of Opdivo vs. dacarbazine chemotherapy in patients who had not received prior therapy. CheckMate -066...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.